Affiliations 

  • 1 Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
  • 2 Department of Dermatology, Hospital Sultanah Aminah, and Clinical School Johor Bahru, Monash University Malaysia, Johor Bahru, Malaysia
  • 3 Icahn School of Medicine at Mount Sinai, New York, New York, USA
  • 4 Department of Dermatology, Hedi Chaker Hospital, University of Sfax, Sfax, Tunisia
  • 5 Department of Dermatology and Allergy, Ludwig-Maximilian-University Munich, Munich, Germany
  • 6 Department of Dermatology, University of São Paulo, São Paulo, Brazil
  • 7 Department of Dermatology, Teikyo University School of Medicine, Tokyo, Japan
  • 8 IQVIA Commercial GmbH & Co., Munich, Germany
  • 9 School of Medicine, Queen's University and Centre for Dermatology and Probity Medical Research, Peterborough, Ontario, Canada
J Eur Acad Dermatol Venereol, 2023 Apr;37(4):737-752.
PMID: 36606566 DOI: 10.1111/jdv.18851

Abstract

BACKGROUND: Generalized pustular psoriasis (GPP) is a rare and highly heterogeneous skin disease, characterized by flares of neutrophilic pustules and erythema. As a rare disease with few clinical studies and no standardized management approaches, there is a paucity of knowledge regarding GPP.

OBJECTIVES: Conduct a Delphi panel study to identify current evidence and gain advanced insights into GPP.

METHODS: A systematic literature review was used to identify published literature and develop statements categorized into four key domains: clinical course and flare definition; diagnosis; treatment goals; and holistic management. Statements were rated on a Likert scale by a panel of dermatologists in two rounds of online questionnaires; the threshold for consensus was agreement by ≥80%.

RESULTS: Twenty-one panellists reached consensus on 70.9%, 61.8%, 100.0% and 81.8% of statements in the 'clinical course and flare definition', 'diagnosis', 'treatment goals' and 'holistic management of GPP' domains, respectively. There was clear consensus on GPP being phenotypically, genetically and immunologically distinct from plaque psoriasis. Clinical course is highly variable, with an extensive range of complications. Clinical and histologic features supporting GPP diagnosis reached high levels of agreement, and although laboratory evaluations were considered helpful for diagnosis and monitoring disease severity, there was uncertainty around the value of individual tests. All acute and long-term treatment goals reached consensus, including rapid and sustained clearance of pustules, erythema, scaling and crust, clearance of skin lesions and prevention of new flares. Potential triggers, associated comorbidities and differential diagnoses achieved low rates of consensus, indicating that further evidence is needed.

CONCLUSIONS: Global consensus between dermatologists was reached on clinically meaningful goals for GPP treatment, on key features of GPP flares and on approaches for assessing disease severity and multidisciplinary management of patients. On this basis, we present a management algorithm for patients with GPP for use in clinical practice.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.